Enhanced Long-Term Care of Severe Respiratory Failure
DESCRIPTION (provided by applicant): Current management of acute respiratory distress syndrome (ARDS) is suboptimal. Arteriovenous carbon dioxide removal (AVCO2R) combined with mild oxygen ventilation has shown promise. AVCO2R is mild pumpless technique using low-pressure drop membrane oxygenators, which reduces labor, cost, complexity and patient stress. While AVCO2R works for short durations, ARDS therapy must operate continuously for weeks.
Phase I successfully demonstrated CMS non-porous membranes significantly enhance AVCO2R membrane long term wet-out resistance while maintaining carbon dioxide removal membrane modules fluid dynamics.
Working closely with University of Texas (UT) we completed short-term in-vivo testing on 10 sheep using UT sheep model. In-vivo results showed CMS AVCO2R system compared favorably to control. Long term in-vivo testing further supported CMS new membrane technology.
Phase II will build upon Phase I feasibility success and first optimize membrane module fabrication. Working with UT we will do extensive in-vitro testing and then perform numerous (40+) long-term sheep studies.
CMS has numerous industrial partners assisting in Phase II system fabrication and subsequent evaluation. These relationships will help Phase II plus identifying appropriate commercialization partners.
Small Business Information at Submission:
COMPACT MEMBRANE SYSTEMS, INC.
325 WATER STREET WILMINGTON, DE 18904
Number of Employees: